Benchmark Holdings Streamlines Operations with Genetics Business Sale Amidst Financial Challenges

Benchmark Holdings ( (GB:BMK) ) has provided an update.

Benchmark Holdings reported a challenging financial year ending September 2024, with total revenues down by 7% at constant currency due to market headwinds and restructuring efforts. The company completed a strategic review resulting in the sale of its Genetics business, which is expected to streamline operations, reduce costs, and strengthen its financial position by focusing on Advanced Nutrition and Health sectors. The disposal should unlock shareholder value and enable a focus on growth and profitability improvements in its core areas.

More about Benchmark Holdings

Benchmark Holdings is an aquaculture biotechnology company that focuses on Advanced Nutrition and Health products aimed at improving animal health and sustainability in aquaculture. The company has been working on innovative solutions such as new shrimp feed technology and sea lice treatments while expanding its market presence, including setting up a subsidiary in India.

YTD Price Performance: -1.03%

Average Trading Volume: 117,219

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £249.3M

Learn more about BMK stock on TipRanks’ Stock Analysis page.